Communications Biology (Aug 2022)
Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1
- Kyohei Matsuura,
- Natsumi Maehara,
- Aika Hirota,
- Ayaka Eguchi,
- Keisuke Yasuda,
- Kaori Taniguchi,
- Akemi Nishijima,
- Nobuyuki Matsuhashi,
- Yoshiyuki Shiga,
- Rumi Ishii,
- Yasuhiro Iguchi,
- Kazunari Tanabe,
- Satoko Arai,
- Toru Miyazaki
Affiliations
- Kyohei Matsuura
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Natsumi Maehara
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Aika Hirota
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Ayaka Eguchi
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Keisuke Yasuda
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Kaori Taniguchi
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Akemi Nishijima
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Nobuyuki Matsuhashi
- Department of Gastroenterology, NTT Medical Center Tokyo
- Yoshiyuki Shiga
- Department of Urology, Robotic Surgical Center, NTT Medical Center Tokyo
- Rumi Ishii
- Department of Urology, Tokyo Women’s Medical University
- Yasuhiro Iguchi
- Medical corporation JISEIKAI
- Kazunari Tanabe
- Department of Urology, Tokyo Women’s Medical University
- Satoko Arai
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- Toru Miyazaki
- Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
- DOI
- https://doi.org/10.1038/s42003-022-03750-w
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 13
Abstract
The circulating protein apoptosis inhibitor of macrophage (AIM) reduces kidney stone development and prevents build up, providing the basis for kidney stone disease therapy.
